SEARCH:   Advanced

Blood, 1 March 2005, Vol. 105, No. 5, pp. 1891-1897. Prepublished online as a Blood First Edition Paper on November 18, 2004; DOI 10.1182/blood-2004-08-3300. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-08-3300v1 105/5/1891    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Spina, M. Articles by Tirelli, U. Search for Related Content PubMed PubMed Citation Articles by Spina, M. Articles by Tirelli, U. Related Collections Neoplasia Clinical Trials and Observations Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials Michele Spina, Ulrich Jaeger, Joseph A. Sparano, Renato Talamini, Cecilia Simonelli, Mariagrazia Michieli, Giuseppe Rossi, Ezio Nigra, Massimiliano Berretta, Chiara Cattaneo, Armin C. Rieger, Emanuela Vaccher, and Umberto Tirelli From the Division of Medical Oncology A and the Epidemiology Unit, National Cancer Institute, Aviano, Italy; the Departments of Hematology and Dermatology, University of Vienna, Austria; the Albert Einstein Cancer Center, Montefiore Medical Center, New York, NY; the Division of Hematology, Civil Hospital, Brescia, Italy; and the Division of Infectious Diseases B, Amedeo di Savoia Hospital, Turin, Italy. Evidence suggests that infusional therapy is a more effective means for administering cytotoxic therapy than intravenous bolus therapy for lymphoma and offers greater potential for therapeutic synergy with rituximab, which has a long half-life. We pooled the results of 3 prospective phase 2 trials evaluating rituximab in combination with 96-hour infusion of cyclophosphamide (187.5-200 mg/m2 per day), doxorubicin (12.5 mg/m2 per day), and etoposide (60 mg/m2 per day) (R-CDE) plus granulocyte–colony-stimulating factor (G-CSF) in 74 patients with HIV-associated, B-cell non-Hodgkin lymphoma, of whom 56 (76%) patients received concurrent highly active antiretroviral therapy (HAART). The complete remission (CR) rate was 70% (95% confidence interval [CI], 59%-81%), and the estimated 2-year failure-free survival and overall survival rates were 59% (95% CI, 47%-71%) and 64% (95% CI, 52%-76%), respectively. Ten (14%) patients had opportunistic infections during or within 3 months of the end of R-CDE, and 17 (23%) patients developed nonopportunistic infections after that time. Six (8%) patients died because of infection; 2 (3%) of those infections were bacterial sepsis during R-CDE, and 4 (5%) were opportunistic infections that occurred between 2 and 8 months after the completion of R-CDE. R-CDE produced a 70% CR rate and a 59% 2-year failure-free survival rate in patients with HIV-associated lymphoma. Consistent with other reports, adding rituximab to cytotoxic therapy in this population may increase the risk for life-threatening infection. Further studies evaluating rituximab in combination with infusional chemotherapy are warranted, but caution is advised. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: HIV-associated lymphoma: promising new results, but with toxicity David J. Straus Blood 2005 105: 1842. [Full Text] [PDF] This article has been cited by other articles: J.-S. Kim, S. J. Kim, J.-S. Kim, E. S. Kim, H.-J. Shin, J. S. Chung, Y.-H. Min, M. H. Lee, Y. J. Choi, S.-M. Bang, et al. Report of Aids-related Lymphoma in South Korea Jpn. J. Clin. Oncol., February 8, 2008; (2008) hym168v1. [Abstract] [Full Text] [PDF] M. Bongiovanni, R. Ranieri, D. Ferrari, C. Codeca, T. Tartaro, and L. Uziel Prolonged survival of an HIV-infected subject with severe lymphoproliferative disease and rhinocerebral mucormycosis J. Antimicrob. Chemother., July 1, 2007; 60(1): 192 - 193. [Full Text] [PDF] M. Spina, C. Simonelli, and U. Tirelli Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma J. Clin. Oncol., February 20, 2007; 25(6): e7 - e7. [Full Text] [PDF] J S Smolen, E C Keystone, P Emery, F C Breedveld, N Betteridge, G R Burmester, M Dougados, G Ferraccioli, U Jaeger, L Klareskog, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis Ann Rheum Dis, February 1, 2007; 66(2): 143 - 150. [Abstract] [Full Text] [PDF] T. M. Habermann Antibody Therapy in Aggressive Lymphomas Hematology, January 1, 2007; 2007(1): 257 - 264. [Abstract] [Full Text] [PDF] C. Palmieri, T. Treibel, O. Large, and M. Bower AIDS-related non-Hodgkin's lymphoma in the first decade of highly active antiretroviral therapy QJM, December 1, 2006; 99(12): 811 - 826. [Abstract] [Full Text] [PDF] F. Boue, J. Gabarre, C. Gisselbrecht, J. Reynes, A. Cheret, F. Bonnet, E. Billaud, M. Raphael, R. Lancar, and D. Costagliola Phase II Trial of CHOP Plus Rituximab in Patients With HIV-Associated Non-Hodgkin's Lymphoma J. Clin. Oncol., September 1, 2006; 24(25): 4123 - 4128. [Abstract] [Full Text] [PDF] M. Bower, D. Mazhar, and J. Stebbing Should Cervical Cancer Be an Acquired Immunodeficiency Syndrome-Defining Cancer? J. Clin. Oncol., June 1, 2006; 24(16): 2417 - 2419. [Full Text] [PDF] S. Combs, N. Neil, and D. M. Aboulafia Liposomal Doxorubicin, Cyclophosphamide, and Etoposide and Antiretroviral Therapy for Patients with AIDS-Related Lymphoma: A Pilot Study. Oncologist, June 1, 2006; 11(6): 666 - 673. [Abstract] [Full Text] [PDF] N. Mounier, M. Spina, J. Gabarre, M. Raphael, G. Rizzardini, J.-B. Golfier, E. Vaccher, A. Carbone, B. Coiffier, G. Chichino, et al. AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy Blood, May 15, 2006; 107(10): 3832 - 3840. [Abstract] [Full Text] [PDF] K. Dunleavy, W. H. Wilson, and L. D. Kaplan The case for rituximab in AIDS-related lymphoma. Blood, April 1, 2006; 107(7): 3014 - 3015. [Full Text] [PDF] W. H. Navarro and L. D. Kaplan AIDS-related lymphoproliferative disease Blood, January 1, 2006; 107(1): 13 - 20. [Abstract] [Full Text] [PDF] A. M. Levine and S.-T. Lim In Reply: J. Clin. Oncol., November 20, 2005; 23(33): 8540 - 8541. [Full Text] [PDF] S.-T. Lim, R. Karim, A. Tulpule, B. N. Nathwani, and A. M. Levine Prognostic Factors in HIV-Related Diffuse Large-Cell Lymphoma: Before Versus After Highly Active Antiretroviral Therapy J. Clin. Oncol., November 20, 2005; 23(33): 8477 - 8482. [Abstract] [Full Text] [PDF] M. Spina, C. Simonelli, R. Talamini, and U. Tirelli Patients With HIV With Burkitt's Lymphoma Have a Worse Outcome Than Those With Diffuse Large-Cell Lymphoma Also in the Highly Active Antiretroviral Therapy Era J. Clin. Oncol., November 1, 2005; 23(31): 8132 - 8133. [Full Text] [PDF] L. D. Kaplan, J. Y. Lee, R. F. Ambinder, J. A. Sparano, E. Cesarman, A. Chadburn, A. M. Levine, and D. T. Scadden Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010 Blood, September 1, 2005; 106(5): 1538 - 1543. [Abstract] [Full Text] [PDF] M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020